Comparable prevalence of distant metastasis and survival of different primary site for LN + pancreatic tumor
Authors:
Open Access
- 1 July 2020
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-18
Abstract
Background: Few studies have delved into the prevalence of distant metastasis (DM +) and survival for patients with lymph node metastases (LN +) by primary site. We aimed to detect differences in distant metastasis and prognosis between pancreatic head and bodytail tumors for LN + patients. Methods: Patients with chemotherapy, histologically diagnosed, primary site between 2004 and 2016 were included from the SEER (Surveillance, Epidemiology, and End Results) database. Pancreatic head tumors were compared with pancreatic bodytail tumors using the odds ratio (OR) for rates of distant metastasis, hazard ratios (HR) for overall survival (OS) and cancer-specific survival (CSS). The competing risk model and propensity score matching (PSM) were performed to further explore. Results: Of 5726 LN + patients identified from the SEER database, pancreatic head tumors account for 85.2% (4877 of 5726) and 14.8% (849 of 5726) were pancreatic bodytail tumors. The incidence of DM was lower in pancreatic head than in pancreatic bodytail tumors (OR, 0.29; 95% CI 0.23–0.37; P < 0.001). The multivariate Cox regression show pancreatic head tumors have a significantly shorter survival rate relative to pancreatic bodytail (HR, 1.12; 95% CI 1.03–1.22; P = 0.008), but the primary site was not a significant independent risk factor for prognosis by log-rank test (P = 0.39) and multivariate competing risk model [subdistribution HR (SHR), 1.08; 95% CI 0.98–1.19; P = 0.087].We then examined our conclusion by 1:1 propensity score matching, and the result reflected pancreatic head tumors have a lower risk of DM compared with pancreatic bodytail tumors (OR, 0.22; 95% CI 0.15–0.34; P < 0.001), but the primary site of pancreatic tumors was not associated with LN + patient survival based on univariate Cox regression (HR, 1.04; 95% CI 0.93–1.17; P = 0.435) and competing risk analysis (SHR, 1.01; 95% CI 0.89–1.12; P = 0.947). Conclusions: LN + pancreatic head tumors were significantly lower risk of DM relative to pancreatic bodytail tumors. Survival outcome in LN + pancreatic tumors didn’t exist significant differences split by primary site, which indicates that the prognosis of LN + patients with chemotherapy isn’t associated with the primary site of metastasis, but with the occurrence of metastasis.Keywords
Funding Information
- Natural Science Foundation of Tianjin Municipality (16JCYBJC27100)
This publication has 34 references indexed in Scilit:
- Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinomaBritish Journal of Surgery, 2016
- Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populationsGastrointestinal Endoscopy, 2016
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Incidence and Survival of Pancreatic Head and Body and Tail CancersPancreas, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line TherapyJapanese Journal of Clinical Oncology, 2008
- Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic CancerOncology, 2007
- Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.2002
- Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database11No competing interests declared.Journal of the American College of Surgeons, 1999